Journal Article Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes

Funakoshi, Shunsuke  ,  Miki, Kenji  ,  Takaki, Tadashi  ,  Okubo, Chikako  ,  Hatani, Takeshi  ,  Chonabayashi, Kazuhisa  ,  Nishikawa, Misato  ,  Takei, Ikue  ,  Oishi, Akiko  ,  Narita, Megumi  ,  Hoshijima, Masahiko  ,  Kimura, Takeshi  ,  Yamanaka, Shinya  ,  Yoshida, Yoshinori

62016-01-08 , Nature Publishing Group
最も移植効果の高い心筋細胞のステージを発見 : ヒトiPS細胞から分化させた心筋細胞の移植効果を高める. 京都大学プレスリリース. 2016-01-08.
Human pluripotent stem cell-derived cardiomyocytes (CMs) are a promising tool for cardiac cell therapy. Although transplantation of induced pluripotent stem cell (iPSC)-derived CMs have been reported in several animal models, the treatment effect was limited, probably due to poor optimization of the injected cells. To optimize graft cells for cardiac reconstruction, we compared the engraftment efficiency of intramyocardially-injected undifferentiated-iPSCs, day4 mesodermal cells, and day8, day20, and day30 purified iPSC-CMs after initial differentiation by tracing the engraftment ratio (ER) using in vivo bioluminescence imaging. This analysis revealed the ER of day20 CMs was significantly higher compared to other cells. Transplantation of day20 CMs into the infarcted hearts of immunodeficient mice showed good engraftment, and echocardiography showed significant functional improvement by cell therapy. Moreover, the imaging signal and ratio of Ki67-positive CMs at 3 months post injection indicated engrafted CMs proliferated in the host heart. Although this graft growth reached a plateau at 3 months, histological analysis confirmed progressive maturation from 3 to 6 months. These results suggested that day20 CMs had very high engraftment, proliferation, and therapeutic potential in host mouse hearts. They also demonstrate this model can be used to track the fate of transplanted cells over a long time.

Number of accesses :  

Other information